Article
Oncology
Jianming Xu, Jieer Ying, Rongrui Liu, Jun Wu, Feng Ye, Nong Xu, Yanqiao Zhang, Rusen Zhao, Xiaojun Xiang, Jianhong Wang, Xiaoyan Lin, Huiting Xu, Shegan Gao, Suxia Luo, Baohong Guo, Xionghui Li, Yangzhi Su, Qian Wang
Summary: This study reports the safety and efficacy results of a phase 2 trial using a novel human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody KN026 in patients with advanced HER2-expressing gastric or gastroesophageal junction cancer. The results showed that KN026 has a favorable safety profile and promising anti-tumor activity.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Wen Zhang, Xiaohong Han, Lin Yang, Yuanyuan Song, Liangzhi Xie, Wenlin Gai, Yan Wang, Yuankai Shi
Summary: SCT200 demonstrated favorable safety, pharmacokinetic profile, and preliminary efficacy in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer, with low toxicity.
Article
Oncology
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: A retrospective evaluation of mCRC patients receiving anti-EGFR monoclonal antibody treatment identified liver metastasis as an independent risk factor for skin toxicities and prophylactic administration of antibiotics as a preventive factor. The study suggests that preemptive antibiotic use can decrease the risk of skin toxicities during anti-EGFR treatment.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Tianyu Zeng, Hai Xu, Yincheng Liu, Chunxiao Sun, Fan Yang, Yan Liang, Xiang Huang, Ziyi Fu, Wei Li, Yongmei Yin
Summary: This study assessed the frequency of lung cancer following breast cancer diagnosis and the associations between the two types of cancer. The results showed that breast cancer patients, especially those with low-grade malignancy, have a higher risk of developing primary lung cancer. Close follow-up is recommended for patients with isolated ground-glass nodules and high-risk factors. Additionally, EGFR may play an important role in primary lung adenocarcinomas and breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Hanna Elomaa, Maarit Ahtiainen, Sara A. Vayrynen, Shuji Ogino, Jonathan A. Nowak, Marjukka Friman, Olli Helminen, Erkki-Ville Wirta, Toni T. Seppala, Jan Bohm, Markus J. Makinen, Jukka-Pekka Mecklin, Teijo Kuopio, Juha P. Vayrynen
Summary: This study evaluated the prognostic significance of tumour cell-T cell co-localisation and T cell densities in colorectal cancer patients. The findings showed that high T cell proximity score was associated with longer cancer-specific survival, indicating the potential of spatial measurement of T cell infiltrates as a novel, robust tumour-immune biomarker.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Taro Sato, Hiroki Osumi, Eiji Shinozaki, Akira Ooki, Keitaro Shimozaki, Daisaku Kamiimabeppu, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
Summary: This study retrospectively analyzed the clinical data of KRAS exon 2 wild type mCRC patients receiving third-line chemotherapy, finding that RAS and BRAF mutations were independent factors affecting efficacy, while primary tumor location and PIK3CA mutation did not influence survival.
ANTICANCER RESEARCH
(2021)
Review
Oncology
Hiroyuki Takeda, Yu Sunakawa
Summary: BRAF mutations are an important poor prognostic factor in mCRC, but greater understanding of patient characteristics through genomic classification allows for more ideal treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Qizhi Tang, Weiyu Pan, Liangyue Peng
Summary: This study assessed the association between Hashimoto thyroiditis (HT) and clinical outcomes of papillary thyroid carcinoma (PTC). The results showed that PTC patients with HT had lower risks of lymph node metastasis, distant metastasis, extrathyroidal extension, recurrence, vascular invasion, and a better 20-year survival rate, while had higher risks of multifocality, perineural infiltration, and bilaterality. This suggests that PTC patients with HT may have favorable clinicopathologic characteristics.
Review
Biochemistry & Molecular Biology
Ahmad Machmouchi, Laudy Chehade, Sally Temraz, Ali Shamseddine
Summary: Targeted monoclonal antibody therapy against EGFR is a leading treatment for mCRC. However, resistance due to KRAS and BRAF mutations has emerged. Cells with these mutations overexpress GLUT1 and SVCT2, leading to intracellular vitamin C transport and cell death. High dose vitamin C shows promise in overcoming EGFR resistance in mCRC with wild KRAS mutation and in patients with KRAS and BRAF mutations, but more clinical trials are needed.
Article
Oncology
Emilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, Audrey Perret, Claire Gallois, Maria Antista, Lorenzo Pilla, Thierry Lecomte, Mario Scartozzi, Emilie Soularue, Lisa Salvatore, Vincent Bourgeois, Massimiliano Salati, David Tougeron, Ludovic Evesque, Jean-Nicolas Vaillant, Reem El-Khoury, Sara Lonardi, Chiara Cremolini, Julien Taieb
Summary: The combination of anti-BRAF and anti-EGFRs shows efficacy in patients with BRAFm mCRC previously treated with an anti-EGFR agent. The results of this retrospective study suggest that this combination could be a valuable treatment option for patients with limited therapeutic alternatives.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Genetics & Heredity
Peter W. Eide, Seyed H. Moosavi, Ina A. Eilertsen, Tuva H. Brunsell, Jonas Langerud, Kaja C. G. Berg, Bard I. Rosok, Bjorn A. Bjornbeth, Arild Nesbakken, Ragnhild A. Lothe, Anita Sveen
Summary: Gene expression-based subtypes of colorectal cancer have clinical significance, but the representativeness of primary tumors and consensus molecular subtypes (CMS) for metastatic cancers remains unclear. Metastases exhibit decreased CMS1/CMS3 signals and increased CMS4 signals, influenced by the microenvironment. The majority of classified metastases are CMS2 or CMS4, with subtype switching and inter-metastatic CMS heterogeneity being common.
NPJ GENOMIC MEDICINE
(2021)
Article
Immunology
Deepali Gupta, Mukesh Kumar, Priyanka Sharma, Trishala Mohan, Amresh Prakash, Renu Kumari, Punit Kaur
Summary: The COVID-19 pandemic caused by SARS-CoV-2 has become a global health problem due to the rapid evolution of the viral genome and the emergence of new variants. Certain co-mutations in the spike protein receptor-binding domain have been found to reduce the binding affinity between the virus and monoclonal antibodies, posing challenges in the development of effective treatments.
Article
Medical Laboratory Technology
Chengfeng Wang, Diling Pan
Summary: This study investigated the relationship between BRAF, KRAS, and PIK3CA mutations and clinicopathologic features and prognosis of colorectal cancer patients. The results showed that the mutant patterns of BRAF, KRAS, and PIK3CA were not associated with the general and clinicopathological features of patients. However, these mutation patterns could be used as independent prognostic factors for colorectal cancer.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Review
Oncology
Junjia Liu, Hao Xie
Summary: This review explores the characteristics, clinical relevance, and treatment possibilities of BRAF non-V600 mutations in colorectal cancer, filling in existing knowledge gaps. Understanding the intricacies of these mutations can help healthcare professionals and researchers develop personalized treatment strategies to improve patient care.
Article
Oncology
Emerik Osterlund, Ari Ristimaki, Markus J. Makinen, Soili Kytola, Juha Kononen, Per Pfeiffer, Leena-Maija Soveri, Mauri Keinanen, Halfdan Sorbye, Luis Nunes, Tapio Salminen, Lasse Nieminen, Aki Uutela, Paivi Halonen, Annika Algars, Jari Sundstrom, Raija Kallio, Raija Ristamaki, Annamarja Lamminmaki, Hanna Stedt, Eetu Heerva, Teijo Kuopio, Tobias Sjoblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund
Summary: BRAF-V600E mutation is a negative prognostic and predictive biomarker in metastatic colorectal cancer. Non-V600E mutations (aBRAFmt) are rare and poorly understood. This study compared the mutation patterns and characteristics of aBRAFmt with other RAS/BRAF groups in three different cohorts. The study found that aBRAFmt represents a distinct subgroup with differences in clinicopathological features, and its prognosis is slightly better than BRAF-V600E but worse than RASmt and RAS & BRAFwt. aBRAFmt should not be a contraindication for metastasectomy.
INTERNATIONAL JOURNAL OF CANCER
(2023)